BCAB

BioAtla, Inc.

Healthcare · Biotechnology

$262.82 sample

-4.07 (-1.52%) 1D

Market cap

$181.5B

Price as of

2026-10-04

Latest filing

8-K · 2026-09-07

Alerts

8

Price$262.82 -0.53% 3M daily closessample

272.26254.32

2026-07-072026-07-292026-08-202026-09-102026-10-02

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 29INSInsider sell: EVP, Operations
Sep 24INSInsider sell: Director
Sep 16INSInsider sell: 10% owner
Sep 07SECForm 144 filed
Sep 01SECDEF 14A filed
Aug 24SEC8-K filed: material event
Aug 13INSInsider sell: General Counsel
Aug 05INSInsider sell: Chief Executive Officer

Sign up to see the real BCAB record →

Company facts

SEC EDGAR registration

Name: BioAtla, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -55sample, -100 to +100
Reporting currency: USD

Who is positioning in BCAB

sample

Insiders: 27 insider transactions over 90 days, net selling, $220.3M
Congress: 2 members traded over 90 days
Institutions · 13F: 20 funds hold $1.7B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$6.3B +16.5% y/y

Q4 2024Q3 2026

Inventory$3.8B +18.6% y/y

Q4 2024Q3 2026

Accounts receivable$2.7B +4.1% y/y

Q4 2024Q3 2026

Total debt$7.4B +16.7% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $28.5B -2.1% 3M
Sample peer B: $153.4B -9.9% 3M
Sample peer C: $37.1B -9.0% 3M
Sample peer D: $134.4B -4.4% 3M
Sample peer E: $34.0B +7.5% 3M